Skip to content

A Randomized Controlled Clinical Study on Corosolic Acid Cream in the Treatment of Mild to Moderate Plaque Psoriasis

A Randomized Controlled Clinical Study on Corosolic Acid Cream in the Treatment of Mild to Moderate Plaque Psoriasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001045
Enrollment
Unknown
Registered
2026-04-22
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Corosolic Acid Treatment Group:2% Corosolic Acid Cream applied twice daily to lesions for 8 weeks, with 8-week follow-up, alongside baseline therapy.
Control Group:Daivonex (Calcipotriol Ointment, LEO Laboratories Limited
15g:0.75mg) applied twice daily to lesions for 8 weeks, with 8-week follow-up, alongside baseline therapy.

Sponsors

Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Integrated Chinese and Western Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet Western clinical diagnostic criteria for plaque psoriasis; 2. BSA =10% (lesions primarily located on trunk and/or limbs, excluding palms/soles, face/scalp, and genital areas); 3. Aged 18-75 years, any gender; 4. Willing to participate and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. History of intolerance to topical vitamin D3 derivatives or herbal topical treatments; 2. Other active skin diseases that may interfere with assessment; 3. Previous use of biologics (etanercept =14d, infliximab =40d, ixekizumab =52d, adalimumab =64d, guselkumab =72d, ustekinumab =84d, secukinumab =108d) or JAK inhibitors =1 week; 4. Severe uncontrolled local/systemic infections; 5. Uncontrolled severe diseases (cardiovascular, respiratory, etc.) or abnormal lab values: ALT/AST >2×ULN; Cr >1.3×ULN; hematologic parameters below LLN; 6. Major surgery within 8 weeks or planned during study; 7. History of malignancy, immunodeficiency, hypersensitivity, or family tumor history; 8. Pregnancy/lactation; 9. Substance abuse history; 10. Other investigator-determined exclusions.

Design outcomes

Primary

MeasureTime frame
Proportion of subjects with =50% improvement in Psoriasis Area and Severity Index (PASI) score from baseline;

Secondary

MeasureTime frame
Psoriasis Body Surface Area;Physician's Global Assessment;Dermatological Quality of Life Index;Recurrence Assessment;

Countries

China

Contacts

Public ContactZhou Mi

Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Integrated Chinese and Western Medicine Hospital

vieky2866@163.com+8613636686022

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026